Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Proteasome inhibition is an effective treatment strategy for multiple myeloma. With improving survival, attention is increasingly focusing on ease of administration and toxicity profile. Ixazomib is an investigational, orally bioavailable 20S proteasome inhibitor. Sixty patients with relapsed and/or...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Kumar, Shaji K., Bensinger, William I., Zimmerman, Todd M., Reeder, Craig B., Berenson, James R., Berg, Deborah, Hui, Ai-Min, Gupta, Neeraj, Di Bacco, Alessandra, Yu, Jiang, Shou, Yaping, Niesvizky, Ruben
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2014
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4468583/
https://ncbi.nlm.nih.gov/pubmed/24904120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-01-548941
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items